A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.

ABSTRACT:

Aims/hypothesis

This 52-week multinational, randomised, open-label, parallel-group, non-inferiority trial compared clinical outcomes following supplementation of oral glucose-lowering drugs with basal insulin analogues detemir and glargine in type 2 diabetic patients.

Methods

Insulin-naive adults (n=582, HbA(1c) 7.5-10.0%, BMI 7.0 mmol/l after achieving FPG <7.0 mmol/l. Due to labelling restrictions, no second glargine dose was allowed.

Results

Baseline HbA(1c) decreased from 8.6 to 7.2 and 7.1% (NS) wit

SUBMITTER: Rosenstock J 

PROVIDER: S-EPMC2235909 | biostudies-literature | 2008 Mar

REPOSITORIES: biostudies-literature